Check out Repatha FDA approval news where we will tell you about the approval of the Amgen cholesterol drug for the prevention of heart attack and stroke.
In a significant advancement for cardiovascular disease management, Amgen’s Repatha (evolocumab) has received approval from the U.S. Food and Drug Administration (FDA) to prevent heart attacks, strokes, and coronary revascularizations in adults with heart disease. This marks the first approval of a PCSK9 inhibitor for these specific conditions, highlighting a major step forward in the […]
Check out details of Amgen Cholesterol Injection phase 3 trial results which demonstrated that Repatha cholesterol injection with statin therapy reduce heart attack, stroke chances.
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in heart attack and stroke risks among patients with heart diseases, according to results from a comprehensive phase 3 cardiovascular outcomes study. Groundbreaking Results in Cardiovascular Prevention The study, named FOURIER, involved 27,564 patients who were at risk […]